COLL Collegium Pharmaceutical, Inc.
QT35Latest market price
23.72
+0.04+0.17%
TA
Loading chart...
Snapshot
| Index | — | P/E | 19.10 | EPS (ttm) | 1.24 | Insider Own | 20.81% | Shs Outstand | 32.56M | Perf Week | 2.02% |
| Market Cap | 770.92M | Forward P/E | 3.26 | EPS next Y | 7.26 | Insider Trans | -0.26% | Shs Float | 31.95M | Perf Month | 7.54% |
| Enterprise Value | 1.50B | PEG | 1.82 | EPS next Q | 1.86 | Short Float | 16.82% | Perf Quarter | -33.73% | ||
| Income | 48.00M | P/S | 0.95 | EPS this Y | -0.16% | Short Ratio | 6.88 | Perf Half Y | -31.52% | ||
| Sales | 808.00M | P/B | 2.47 | EPS next Y | -2.68% | ROA | 2.24% | Short Interest | 5.38M | Perf YTD | -48.86% |
| Book/sh | 9.58 | P/C | 5.98 | EPS next 5Y | 10.52% | ROE | 15.96% | 52W High | 50.79 -53.30% | Perf Year | -33.58% |
| Cash/sh | 3.96 | P/FCF | 2.35 | EPS past 3/5Y | — 17.88% | ROIC | 6.10% | 52W Low | 21.43 10.69% | Perf 3Y | 8.13% |
| Dividend Est. | — | EV/EBITDA | 3.17 | Sales past 3/5Y | 18.95% 20.30% | Gross Margin | 60.02% | Volatility | 2.95% 3.17% | Perf 5Y | 10.91% |
| Dividend TTM | — | EV/Sales | 1.85 | EPS Y/Y TTM | 19.97% | Oper. Margin | 19.61% | ATR (14) | 0.84 | Perf 10Y | 29.40% |
| Dividend Ex-Date | — | Quick Ratio | 0.84 | Sales Y/Y TTM | 14.29% | Profit Margin | 5.93% | RSI (14) | 55.42 | Recom | 2.42 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.03 | EPS Q/Q | 14.29% | SMA20 | 3.62% | Beta | 0.73 | Target Price | 48.00 |
| Payout | 0.00% | Debt/Eq | 2.74 | Sales Q/Q | 6.38% | SMA50 | 1.93% | Rel Volume | 0.72 | Prev Close | 23.68 |
| Employees | 423 | LT Debt/Eq | 2.57 | Earnings | Nov 05 | SMA200 | -28.51% | Avg Volume | 830.04K | Price | 23.72 |
| IPO Date | May 07, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 11.69% 0.13% | Net Debt/EBITDA | 1.54 | Volume | 600,667 | Change | 0.17% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-23-26 | Initiated | Oppenheimer | Outperform | $50 |
| Sep-09-26 | Initiated | Leerink | Outperform | $45 |
| Sep-09-26 | Reiterated | Truist Securities | Buy | $58 → $49 |
| Aug-19-26 | Reiterated | Barclays | Overweight | $56 → $48 |
| Feb-10-26 | Reiterated | Truist Financial | Buy | $55 → $58 |
| Jan-09-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $60 |
| Jan-09-26 | Reiterated | Barclays | Overweight | $58 → $56 |
| Jan-07-26 | Reiterated | Truist Financial | Buy | $47 → $55 |
| Dec-08-25 | Initiated | Barclays | Overweight | $58 |
| Feb-04-25 | Reiterated | Piper Sandler | Neutral | $37 → $36 |
Latest News· Times ET
Oct-30-26
Oct-30-2612:29PM
Oct-29-26
Oct-29-2611:06AM
08:00AM
Oct-26-26
Oct-26-2607:42PM
Oct-22-26
Oct-22-2608:00AM
Oct-21-26
Oct-21-2608:00AM
Oct-19-26
Oct-17-26
Oct-17-2612:18PM
Oct-16-26
Oct-16-2610:55AM
Oct-09-26
Oct-09-2601:32PM
Oct-07-26
Oct-06-26
Oct-06-2608:00AM
Oct-05-26
Oct-05-2602:29AM
Sep-28-26
Company
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 808 | 781 | 631 | 567 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 323 | 317 | 254 | 241 | — | — | — | — | — | |
| Gross Profit | 484 | 463 | 377 | 326 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 241 | 276 | 183 | 159 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 86 | 0 | 24 | 0 | — | — | — | — | — | |
| Operating Income | 159 | 187 | 170 | 167 | — | — | — | — | — | |
| Interest Expense | 163 | 82 | 74 | 83 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 82 | -12 | 3 | -8 | — | — | — | — | — | |
| Net Income Before Taxes | 77 | 93 | 99 | 76 | — | — | — | — | — | |
| Income Taxes | 30 | 30 | 29 | 28 | — | — | — | — | — | |
| Consolidated Net Income | 48 | 63 | 69 | 48 | — | — | — | — | — | |
| Net Income From Continuing Operations | 48 | 63 | 69 | 48 | — | — | — | — | — | |
| Net Income | 48 | 63 | 69 | 48 | — | — | — | — | — | |
| EPS (Recurring) | 1.53 | 1.98 | 2.14 | 1.60 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.53 | 1.98 | 2.14 | 1.60 | — | — | — | — | — | |
| EPS (Diluted) | 1.24 | 1.73 | 1.86 | 1.29 | — | — | — | — | — | |
| EBITDA | 473 | 401 | 342 | 308 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 19.13 | 26.76 | 15.40 | 23.86 | — | — | — | — | — | |
| Price To Sales Ratio | 0.94 | 1.90 | 1.45 | 1.85 | — | — | — | — | — | |
| Gross Margin | 59.90 | 59.28 | 59.75 | 57.50 | — | — | — | — | — | |
| Operating Margin | 19.68 | 23.94 | 26.94 | 29.45 | — | — | — | — | — | |
| Net Margin | 5.94 | 8.07 | 10.94 | 8.47 | — | — | — | — | — | |
| Shares Outstanding | 32 | 32 | 32 | 34 | — | — | — | — | — | |
| Market Capitalization | 759 | 1,482 | 917 | 1,047 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SANTINI GINO | Director | Jun 08 '26 | Option Exercise | 16.49 | 8,700 | 143,463 | 112,483 | Jun 10 |
| Freund John Gordon | Director | May 18 '26 | Sale | 34.05 | 20 | 681 | 83,952 | May 20 |
| Freund John Gordon | Director | May 15 '26 | Sale | 34.54 | 4,127 | 142,547 | 83,972 | May 18 |
| Freund John Gordon | Director | May 15 '26 | Option Exercise | 16.49 | 8,700 | 143,463 | 88,099 | May 18 |
| Lurker Nancy | Director | May 13 '26 | Sale | 35.97 | 4,500 | 161,861 | 18,017 | May 15 |
| BOHLIN GAREN G | Director | May 11 '26 | Option Exercise | 16.49 | 8,700 | 143,463 | 70,959 | May 13 |
| BOHLIN GAREN G | Director | May 11 '26 | Sale | 37.18 | 8,700 | 323,491 | 62,259 | May 13 |
| Dieter David | EVP & General Counsel | Mar 18 '26 | Sale | 34.92 | 13,976 | 488,099 | 77,071 | Mar 20 |
| Dieter David | EVP & General Counsel | Mar 09 '26 | Sale | 36.65 | 6,224 | 228,110 | 91,047 | Mar 11 |
| Dreyer Scott | EVP & Chief Commercial Officer | Mar 03 '26 | Sale | 40.41 | 49,976 | 2,019,436 | 71,770 | Mar 05 |
| Dreyer Scott | EVP & Chief Commercial Officer | Dec 08 '25 | Option Exercise | 15.90 | 17,600 | 279,840 | 121,213 | Dec 10 |
| Dreyer Scott | EVP & Chief Commercial Officer | Dec 08 '25 | Sale | 48.17 | 17,600 | 847,856 | 103,613 | Dec 10 |
| Balice-Gordon Rita J. | Director | Dec 05 '25 | Sale | 47.03 | 3,650 | 171,673 | 52,629 | Dec 09 |
| Fallon John A. | Director | Nov 12 '25 | Option Exercise | 12.41 | 34,853 | 432,578 | 99,487 | Nov 14 |
| Fallon John A. | Director | Nov 12 '25 | Sale | 47.21 | 34,853 | 1,645,536 | 64,634 | Nov 14 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.